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Abstract
© 2018 Bentham Science  Publishers.  Neurodegenerative  disorders  have been and remain
persistent sources of enormous suffering throughout human history. The tragedy of their impact
on human relationships,  physical  vitality,  and fundamental  dignity  cannot  be  understated.
Parkinson’s disease (PD), one of the most common of these terrible illnesses, has a global
incidence of approximately two-to-four percent of the human population, along with devastating
social and economic impact. The present review analyzes aspects of PD pathophysiology that
offer particularly attractive strategies for the development of improved prevention and therapy.
The occurrence, symptoms, pathogenesis, and etiology of PD are considered, with focus on how
the Alpha synuclein protein, which normally regulates neurotransmitter release, is aggregated
by oxidative stressors into toxic inclusions, prominently including Lewy bodies and insoluble
fibrils that disrupt the organization of brain areas responsible for motor control. The contribution
to a progressively prooxidant tissue environment resulting from interaction between advanced
glycation end products (AGEs) and their cognate receptors (RAGEs) is examined here as a
significant driver of PD. This review also explores strategies currently being developed by a U.S.-
Russian team that  may reduce the risk  and severity  of  PD by use of  recombinant  atoxic
derivatives (ad) of botulinum neurotoxins (BoNT/A ad), that traffic inducers of the cytoprotective
enzyme heme oxygenase to selected midbrain neurons, at which Alpha synuclein aggregation
occurs. Considered together, the topic material presented here provides both researchers and
clinicians with a short but concise overview of the current understanding of PD pathology and
approaches to biotherapeutic (precision) countermeasures to its onset and progression.
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